For many patients, clinical research offers early access to emerging therapies and advanced technology. The staff and physicians at Baylor Scott & White Cardiac Surgery Specialists are committed to delivering improved cardiovascular medical care through new and innovative therapies. Our physicians participate in important national and international clinical trials and embrace every opportunity to provide patients with advanced drug and treatment options.
Sponsored by Medtronic, the purpose of this study is to evaluate the safety and effectiveness of the Valiant Thoracic Stent Graft System in the treatment of acute, complicated Type B aortic dissections (a tear in the lining of the aorta) in the section of the aorta that lies in the chest.
The OPTION study (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) is an investigator-initiated trial designed to evaluate the equivalence of minimally invasive Endoscopic Vessel Harvesting (EVH) in Coronary Artery Bypass Graft surgery (CABG) compared with historical data for open vein harvesting. The study standardizes a number of important factors to optimize the procedure and to improve outcomes.
The purpose of this investigator-initiated study is to identify differences in gene expression in patients with bicuspid and tricuspid aortic valve disease with and without dilation of the ascending aorta.
Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the treatment of Critical Limb Ischemia due to Peripheral Arterial Occlusive Disease
This pivotal study, sponsored by Harvest Technologies, is designed to show the safety and effectiveness of an investigational treatment for Critical Limb Ischemia. The investigational treatment involves removing stem cells from the patient’s own bone marrow and injecting them into the leg to possibly improve blood flow.
The primary aim of this data collection is a three-way comparison of the Maquet Minimal Extra-Corporeal Circulation (M.E.C.C.) System, the conventional heart-lung machine, and off-pump surgery in the setting of coronary artery bypass grafting. We are offering a new, less invasive cardiopulmonary bypass option to our patients. Additionally, we will be using advanced genomic mapping to evaluate our patients, which will offer the possibility of identifying numerous genetic markers in the blood that may help us better understand changes during open heart surgery.
Monday - Friday
8:30 am - 5:00 p.m.
For patients seeking more information regarding a condition or treatment, we recommend the following online resources.